1-3 of 3
Carmelo Rizzari
Close
Sort by
Journal Articles

The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG study

Clinical Trials & Observations
Nobuko Hijiya, Alexey Maschan, Carmelo Rizzari, Hiroyuki Shimada, Carlo Dufour, Hiroaki Goto, Hyoung Jin Kang, Terri Guinipero, Zeynep Karakas, Francisco Bautista, Stéphane Ducassou, Keon Hee Yoo, Christian Michel Zwaan, Frédéric Millot, Briana C. Patterson, Jill Samis, Miguel Izquierdo, Ksenia Titorenko, Sai Li, Darintr Sosothikul
Journal: Blood Advances
Blood Adv (2023) 7 (23): 7279–7289.
https://doi.org/10.1182/bloodadvances.2023010122
Published: 2023
Includes: Supplemental data
Journal Articles

ALL blasts drive primary mesenchymal stromal cells to increase asparagine availability during asparaginase treatment

Martina Chiu, Giuseppe Taurino, Erica Dander, Donatella Bardelli, Alessandra Fallati, Roberta Andreoli, Massimiliano G. Bianchi, Cecilia Carubbi, Giulia Pozzi, Laura Galuppo, Prisco Mirandola, Carmelo Rizzari, Saverio Tardito, Andrea Biondi, Giovanna D’Amico, Ovidio Bussolati
Journal: Blood Advances
Blood Adv (2021) 5 (23): 5164–5178.
https://doi.org/10.1182/bloodadvances.2020004041
Published: 2021
Includes: Supplemental data
Journal Articles

A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety

Clinical Trials & Observations
Nobuko Hijiya, Alexey Maschan, Carmelo Rizzari, Hiroyuki Shimada, Carlo Dufour, Hiroaki Goto, Hyoung Jin Kang, Terri Guinipero, Zeynep Karakas, Francisco Bautista, Stéphane Ducassou, Keon Hee Yoo, Christian Michel Zwaan, Frédéric Millot, Briana Patterson, Jill Samis, Paola Aimone, Alex Allepuz, Ksenia Titorenko, Darintr Sosothikul
Journal: Blood Advances
Blood Adv (2021) 5 (14): 2925–2934.
https://doi.org/10.1182/bloodadvances.2020003759
Published: 2021
Includes: Supplemental data